Association Between Bone Mineral Density and the Use of Nonsteroidal Anti‐Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity

BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the Health ABC cohort (n = 2853). Significantly higher BMD was found in users of relative COX‐2 selective NSAIDs with aspirin (COX‐2/ASA) compared with nonusers. This suggests a role for COX‐2/ASA in osteoporosis.

[1]  C. Brideau,et al.  A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors , 1996, Inflammation Research.

[2]  J. M. Guralnik,et al.  Drug data coding and analysis in epidemiologic studies , 1994, European Journal of Epidemiology.

[3]  J. B. Baumann-Grace,et al.  Fixation of certain heterogenous antigenic substances on bacterial cells and endospores , 1959, Experientia.

[4]  L. Raisz,et al.  Prostaglandins: Mechanisms of action and regulation of production in bone , 2005, Osteoporosis International.

[5]  H. Genant,et al.  Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women , 1995, Calcified Tissue International.

[6]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[7]  M. Visser,et al.  Determinants of Bone Mineral Density in Older Men and Women: Body Composition as Mediator , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[9]  T J Beck,et al.  Does Body Size Account for Gender Differences in Femur Bone Density and Geometry? , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  B. van der Burg,et al.  4-Hydroxytamoxifen Trans-Represses Nuclear Factor-κB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)α, and Not through ERβ. , 2001, Endocrinology.

[11]  L. Raisz.  Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. , 2001, The American journal of medicine.

[12]  B. van der Burg,et al.  4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta. , 2001, Endocrinology.

[13]  H. Schröder,et al.  Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin. , 2000, Free radical biology & medicine.

[14]  A. Stewart,et al.  Bone mineral density in osteoarthritis , 2000, Current opinion in rheumatology.

[15]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[16]  S. Morham,et al.  Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. , 2000, The Journal of clinical investigation.

[17]  M. Feldman,et al.  Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity? , 2000, Annals of Internal Medicine.

[18]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[19]  D. Reid,et al.  Evidence for a Pathogenic Role of Nitric Oxide in Inflammation‐Induced Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  S. Abramson,et al.  The pleiotropic functions of aspirin: mechanisms of action , 1999, Cellular and Molecular Life Sciences CMLS.

[21]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[22]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H K Genant,et al.  Assessment of vertebral bone mineral density using volumetric quantitative CT. , 1999, Journal of computer assisted tomography.

[24]  E. Barrett-Connor,et al.  Nonsteroidal Anti‐Inflammatory Drugs and Bone Mineral Density in Older Women: The Rancho Bernardo Study , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  C. Clish,et al.  Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. , 1998, The Journal of pharmacology and experimental therapeutics.

[26]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[27]  Y. Ma,et al.  The in vivo anabolic actions of prostaglandins in bone. , 1997, Bone.

[28]  S. Cummings,et al.  Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. , 1997, The Journal of rheumatology.

[29]  H. Kawaguchi,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Transcriptional Induction of Cyclooxygenase-2 in Osteoblasts Is Involved in Interleukin-6-Induced , 2022 .

[30]  T. Hangartner,et al.  Evaluation of cortical bone by computed tomography , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  L. Raisz,et al.  Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure‐activity relations and signal transduction pathway , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  H. Blair,et al.  Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. , 1996, Pediatric pathology & laboratory medicine : journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association.

[33]  M. Nevitt,et al.  Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[35]  C. Serhan,et al.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Raisz.  Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. , 1995, The Journal of nutrition.

[37]  S. Iacobelli,et al.  Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.

[38]  R. Copeland,et al.  Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Murakami,et al.  Mammalian non-pancreatic phospholipases A2. , 1993, Biochimica et biophysica acta.

[41]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[42]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[43]  C. A. Davis,et al.  Vertebral mineral determination by quantitative computed tomography (QCT): accuracy of single and dual energy measurements. , 1988, Journal of computer assisted tomography.

[44]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.